Vaccinia immune globulin intravenous (human) - Biologic Drug Details

Summary for vaccinia immune globulin intravenous (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for vaccinia immune globulin intravenous (human)

Recent Clinical Trials for vaccinia immune globulin intravenous (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Providence Health & Services	Phase 2
National Eye Institute (NEI)	Phase 2

See all vaccinia immune globulin intravenous (human) clinical trials

Pharmacology for vaccinia immune globulin intravenous (human)

Mechanism of Action	Virus Neutralization
Physiological Effect	Passively Acquired Immunity
Established Pharmacologic Class	Human Immunoglobulin G
Chemical Structure	Immunoglobulins

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for vaccinia immune globulin intravenous (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for vaccinia immune globulin intravenous (human) Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for vaccinia immune globulin intravenous (human) Derived from Patent Text Search

No patents found based on company disclosures

Vaccinia Immune Globulin Intravenous (Human): Market Dynamics and Financial Trajectory

Last updated: April 25, 2026

What is vaccinia immune globulin intravenous (human) and how is it positioned commercially?

Vaccinia immune globulin intravenous (human) (VIGIV) is a plasma-derived biologic containing antibodies against vaccinia virus. In the U.S., it is marketed as VIGIV (Vaccinia Immune Globulin Intravenous [Human]) under SIGA Technologies branding history for the U.S. smallpox-related countermeasure portfolio and sits within the broader category of Category B or C countermeasures depending on jurisdictional and regulatory framing.

Commercial positioning is driven by two forces that shape its market dynamics:

1. Low baseline endemic demand

   • VIGIV is targeted to specific indications tied to exposure risk (historically smallpox and related orthopox response).
   • That creates demand volatility tied to public health posture, stockpiling, and procurement cycles rather than routine commercial utilization.

2. Government procurement is the dominant buyer

   • The product’s demand profile is typically anchored in government contracting, strategic stockpiles, and emergency readiness frameworks rather than steady hospital formularies.

In business terms, the “market” is not an open-ended branded consumption market. It is procurement-centric and scenario-dependent.

---

How do market dynamics affect sales volume and pricing?

Demand drivers

Driver	Mechanism	Impact on volume
Public health preparedness spending	Stockpile build or replenishment via government contracts	Step-changes in units and revenue timing
Emergency authorization or outbreak events	Unplanned demand surges if exposure scenarios occur	Rapid volume spikes in short windows
Contracting and inventory rotation	Periodic re-contracting for preparedness	Repeat procurement cycles, often not continuous
Clinical guideline evolution	Shifts in preferred countermeasure use	Can move volume between products within orthopox response portfolios

Supply and unit economics constraints

Plasma-derived products often face:

• sourcing constraints (plasma availability),
• fractionation and purification throughput limits,
• lot-to-lot manufacturing variability and release timing,
• and working capital intensity tied to plasma collection and manufacturing schedules.

For VIGIV specifically, these constraints matter because demand is irregular. That increases the risk that manufacturing schedules become misaligned with procurement patterns, which in turn affects revenue recognition timing and gross margin stability.

---

What is the financial trajectory shaped by these dynamics?

A procurement-based biologic like VIGIV typically shows a financial pattern that investors and planners recognize across other countermeasure products:

1. Revenue is lumpy

   • Sales track contract awards, deliveries, and replenishment cycles.
   • You often see revenue concentrated in discrete quarters tied to procurement and fulfillment timing.

2. Gross margin is volatile

   • Plasma-based manufacturing has cost structures that do not scale linearly with low utilization.
   • Underutilization risk can pressure margin when volumes fall below planned run rates.

3. Operating expense pressure can persist

   • Even when sales are low, regulatory maintenance, pharmacovigilance, manufacturing oversight, and commercial contracting keep baseline cost.

4. Working capital swings

   • Inventory build for readiness and the time lag between procurement award and manufacturing release can drive cash flow volatility.

Because VIGIV’s demand is non-recurring in many years, its financial trajectory usually depends more on:

• the size and timing of government contracts,
• ability to maintain manufacturing readiness cost-effectively,
• and contract renewal terms (including reimbursement, inventory agreements, and delivery schedules) than on broad commercial payer coverage.

---

What is the competitive and strategic landscape for orthopox immune countermeasures?

Competitive set

VIGIV competes for limited “orthopox exposure response” procurement budgets rather than across a large chronic market. Competitive positioning tends to center on:

• Other immune globulins (where available)
• Vaccination strategy support (orthopox vaccines and post-exposure prophylaxis frameworks)
• Broader countermeasure portfolios held by companies with government relationships

Strategic implications

• If governments prioritize readiness for multiple orthopox threats, procurement can bundle multiple assets.
• If a single asset is considered “must-have” for exposure scenarios, it can earn a steadier place in preparedness contracts.

For VIGIV, the key is whether contracting authorities fund it as a standalone product or as part of a portfolio with defined emergency procurement triggers.

---

How do regulatory status and reimbursement structure influence commercialization?

VIGIV is subject to:

• biologics manufacturing controls,
• lot release testing,
• and risk management requirements typical for plasma-derived immune globulins.

Commercial reimbursement is often not “standard payer reimbursement” in the way chronic care drugs are. For emergency preparedness products, reimbursement and procurement can be structured through:

• government acquisition channels,
• emergency use frameworks,
• and contract-specific pricing terms.

This tends to mean:

• pricing power is narrower than in routine branded markets,
• and revenue realization depends more on contract mechanics than on commercial formularies.

---

What signals should investors track for VIGIV market timing and returns?

Procurement and supply-chain indicators

Indicator	Why it matters
Contract award size and delivery schedule	Determines revenue timing and inventory draw profile
Manufacturing campaign completion and lot release	Impacts shipment readiness and recognition
Stockpile replenishment frequency	Determines repeat procurement opportunities
Government budget allocations for countermeasures	Drives near-term procurement likelihood

Financial statement metrics

Metric	Interpretation for VIGIV
Revenue concentration by quarter	Confirms procurement-driven dynamics
Gross margin trend vs utilization	Shows whether fixed costs are being leveraged
Operating expense run rate	Indicates cost discipline during low sales periods
Cash flow volatility	Reflects inventory and contract milestone timing

---

What does the financial trajectory imply for planning and valuation?

Base case economics for a preparedness-biologic

A procurement-based product like VIGIV typically has valuation sensitivity to:

• probability-weighted contract wins,
• expected replenishment cycles,
• cost structure leverage from manufacturing utilization,
• and the time lag between contract award and shipment.

Key value drivers

1. Contract continuity
   • Repeat government procurements reduce revenue uncertainty.
2. Manufacturing readiness cost control
   • Maintaining capacity without overbuilding inventory improves margin resilience.
3. Regulatory and product lifecycle management
   • Label stability and ongoing compliance support contract confidence and procurement eligibility.

---

Key Takeaways

• VIGIV’s market is procurement-driven, with demand concentrated around public health preparedness spending, stockpiling, and orthopox response frameworks rather than steady commercial consumption.
• Sales are inherently lumpy, tied to contract awards, delivery schedules, and inventory rotation cycles.
• Gross margin and cash flow are volatile because plasma-derived manufacturing has fixed readiness and utilization risks that do not scale smoothly in low-demand years.
• Financial trajectory is most sensitive to government contracting outcomes (size, timing, and delivery terms) and to the company’s ability to control manufacturing readiness costs while maintaining supply.

---

FAQs

1) Who typically buys vaccinia immune globulin intravenous (human)?

Government and preparedness procurement entities are the dominant buyers due to the product’s exposure-response role.

2) Why does revenue for this biologic tend to be lumpy?

Sales align with contract award timing, inventory replenishment, and emergency readiness fulfillment rather than recurring routine prescribing.

3) What drives near-term sales timing most?

Delivery schedules tied to government contracts and manufacturing lot release timing.

4) What financial metrics best reflect operational leverage for VIGIV?

Gross margin trend relative to utilization, operating expense run rate during low-sales periods, and cash flow volatility tied to inventory and milestone payments.

5) How does competition affect VIGIV’s commercial outlook?

Competition mainly occurs for orthopox countermeasure budget allocation, where portfolios and contracting strategies can shift procurement between assets rather than competing for broad payer formularies.

---

References

[1] U.S. Food and Drug Administration. “Vaccinia Immune Globulin Intravenous (Human) (VIGIV) Prescribing Information / Product Label.” FDA (accessed via FDA labeling repositories).